

ORIGINAL RESEARCH

Evaluation of the NS-1 antigen detection test for early diagnosis of dengue infection

Dr.Ashish Kumar Joshi

Assistant Professor, Department of Biochemistry, Index Medical College, Indore, Madhya Pradesh, India

Corresponding Author

Dr.Ashish Kumar Joshi

Assistant Professor, Department of Biochemistry, Index Medical College, Indore, Madhya Pradesh, India

Received: 03July, 2023

Accepted: 06July, 2023

ABSTRACT

Background: Acute febrile dengue fever is an arbo-viral illness that mostly affects tropical and subtropical regions worldwide. Over the past 50 years, the disease's incidence has grown, and 2.5 billion people now live in dengue-endemic areas. This study aims to assess the NS1 Ag test as a novel diagnostic tool for dengue virus infection early detection in a tertiary care setting. **Materials and Procedures:** From January 2023 to June 2023, this study was carried out in a tertiary care centre at Index Medical College Indore. Serum samples from 500 patients collected. **Result:** 500 suspected dengue fever samples were collected, of which 80 patients were found to be NS1 antigen positive. **Conclusion:** An intensive laboratory-based disease surveillance strategy that can offer early warning of approaching epidemic transmission is necessary for the effective prevention and control of the dengue outbreak.

Key words: NS1 antigen, dengue fever

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

INTRODUCTION

Acute febrile dengue fever is an arbo-viral illness that mostly affects tropical and subtropical regions worldwide. Over the past 50 years, the disease's incidence has grown, and 2.5 billion people now live in dengue-endemic areas¹. Up to 100 million people may be impacted annually; there are 500,000 instances of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) and about 30,000 fatalities, the majority of which are in children².

Non-structural protein 1, or NS1, is a highly conserved glycoprotein that the virus produces in both membrane-associated and secretory forms and is necessary for the survival of DV⁷. Early in the disease's clinical course, DV-infected patients' sera have shown significant amounts of NS1 antigen (NS1 Ag), according to enzyme-linked immunosorbent tests (ELISA) targeting it⁷. A novel method for identifying acute DV infection is the measurement of secretory NS1 protein³.

This study aims to assess the NS1 Ag test as a novel diagnostic tool for dengue virus infection early

detection in a tertiary care setting.

MATERIAL METHOD

From January 2023 to June 2023, this study was carried out in a tertiary care centre at Index Medical College Indore. Serum samples from 500 patients who attended various outdoor causality services and indoor patients who were clinically suspected of being probable cases (defined as any acute febrile illness with one or more of the following symptoms: myalgia, headache, retro-orbital pain, bleeding, altered sensorium, shock, or low platelet count) were received and registered in the study. A thorough physical examination, baseline investigations, and a clinical history were conducted.

Every suspected patient had five millilitres of blood drawn, and the serum was separated and subjected to an Immunochromatography (ICT) based RDT lateral flow assay (J Mitra & Co Pvt Ltd, New Delhi) to test for the presence of NS 1Ag and IgM and IgG anti-dengue antibodies. Tests were run, and the results were read in accordance with the available literature.

RESULT AND DISCUSSION**RESULTS OF SAMPLE SCREENED FOR DENGUE SEROLOGY**

Total sample	NS1 positive	Antibody positive	IgM positive	IgG positive
500	80	45	35	10

The isolation of the virus in cell culture, the detection of virus-specific antibodies, or the identification of viral antigens or nucleic acid are typically required for laboratory confirmation of dengue infection⁴. During the acute phase of the disease, direct virus detection may be utilised to identify dengue infections early, conclusively and specifically by serotype. Serum, plasma, whole blood, and infected tissues can contain live viruses or virus components (RNA or antigens) from 0 to 7 days after the onset of symptoms, which roughly corresponds to the duration of fever. Laboratories rarely carry out direct virus detection techniques, and there aren't many commercially validated kits to help with dengue diagnosis in this location. Compared to methods like cell culture or RNA detection, serological tests are easier to perform and are therefore more frequently utilised to diagnose dengue infections⁵.

Viability of the virus depends on NS1, a highly conserved nonstructural glycoprotein released by virus-infected cells during the acute phase of dengue⁶. All DENV serotypes have uniform circulation of NS1 Ag, which is highly circulated during the initial few days of sickness⁷. Its increased detection rate in acute phase sera is due to this. The diagnostic method for acute infections, which still involves the detection of specific IgM by MAC-ELISA, has the drawback of causing antibodies to take longer to manifest-5-10 days for primary dengue virus infections, and 4-5 days for secondary infections⁸.

CONCLUSION

An intensive laboratory-based disease surveillance strategy that can offer early warning of approaching epidemic transmission is necessary for the effective prevention and control of the dengue outbreak. Consequently, in comparison to IgM antibody detection, NS1 Ag detection is a more useful method for the early diagnosis of DEN infection. Additionally, our research supports the conclusions of other authors who recommend using quick tests for diagnosis and surveillance following appropriate national agency validation for the detection of DEN NS1 Ag in addition to antibody assays.

SOURCE OF FUNDING:None.

CONFLICTS OF INTEREST: None declared.

REFERENCES

1. Smith AW, Chen LH, Massad E, Wilson ME. Threat of dengue to blood safety in dengue-endemic countries. *Emerg Infect Dis* 2009;15:8-11.
2. Guzman MG, Kouri G. Dengue: an update. *Lancet Infect Dis* 2002;2:33-42.
3. Dussart P, Labeau B, Lagathu G, Louis P, Nunes MRT, Rodrigues SG, *et al.* Evaluation of an Enzyme Immunoassay for detection of dengue

4. Guzman, M G. & Kouri, G. Dengue diagnosis, advances and challenges. *Int J Infect Dis.*2004 Mar;8(2):69-80. Doi:http://dx.doi.org/10.1016/j.ijid.2003.03.003.
5. Vaughn, DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S *et al.* Dengue viremia titer, antibody response pattern and virus serotype correlate with disease severity. *J Infect Dis.*2000 Jan;181(1): 2–9. Doi:10.1086/315215.
6. Hang VT, Nguyet NM, Trung DT, Tricou V, Yoksan S, Dung NM *et al.* Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. *PLoS Negl Trop Dis* 2009;3:e360. Doi:10.1371/journal.pntd.0000360.
7. Bessoff K, Delorey M, Sun W, Hunsperger E. Comparison of two commercially available dengue virus (DENV) NS1 capture enzyme-linked immunosorbent assays using a single clinical sample for diagnosis of acute DENV infection. *Clin Vaccine Immunol.* 2008 Oct 15(10);:1513-8. doi:10.1128/CVI.00140-08.
8. Datta S, Wattal C. Dengue NS1 antigen detection: A useful tool in early diagnosis of dengue virus infection. *Indian J Med Microbiol* 2010;28(2):107-10. Doi:10.4103/0255-0857.62484